NXS (ASX) Retraction of Update 9/6

NXS

Click for more information

5.00%

21.0¢ next science limited

First 20 Last

Share
Profile

Follow
buddy134

24,386 Posts.

176

11/06/14

00:11

Post #: 13507912
Share

Originally posted by FlyingDr ↑

Our illustrious management at Nexus continue to emphasis the preferred value of Nil under administration.

Here is a quote from the Independent Expert's Report, page 5.

"... we have calculated the value of a share in Nexus ( on a control basis) under the orderly realisation of assets method to be in the range AUD (0.03) to AUD 0.03 with a calculated preferred value of nil".

I would like to point out that our Independent Expert, that I believe has been overly conservative in their valuation of exploration assets, does give some possibility of a 3 cent return. If Nexus choose to threaten NexusBattle with inaccuracies in their web postings, in fairness, the full unabridged version of the IE statements should be presented to give balance to their arguments.

Of course, there is the possibility of a negative return.

Balance and informed statements is all I ask.

FlyingDr

""""Balance and informed statements is all I ask.""""

Is that all Flying Dr..???

I ask for more than that. I ask for an Independent Auditor and/or Investigator to find out as to how we finished up in such a mess.

I hope that the Administrator, when appointed, will look at all possible angles in determine what has happened.

And, IMO, there is no way known that The Seven Group will be able to call the shots to the Administrator. Until he will be able to make a final decision, SGH will have to sit up and take notice.

Yes, IMO, there will be a Creditors meeting called and SGH will have a big say in determining if we are to be going in liquidation or if we are going to trade our way out of the mess we are in. Nevertheless, the Administrator will have to do a proper research as to the viability of the company and it's assets value before putting it to the Creditors.

Dyor!!!

Expand

NXS Price at posting: 1.1¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 3 more messages in this thread...

First 20 Last

Add NXS (ASX) to my watchlist

(20min delay)
Last 21.0¢		Change 0.010(5.00%)		Mkt cap ! $61.35M

Open	High	Low	Value	Volume
21.0¢	21.0¢	21.0¢	$1.035K	4.928K

Buyers (Bids)

No.	Vol.	Price($)
2	22957	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
22.5¢	5000	1

View Market Depth

No.	Vol.	Price($)
2	22957	0.190
5	76783	0.185
6	118894	0.180
2	23800	0.175
1	17500	0.170

Price($)	Vol.	No.
0.225	5000	1
0.230	1298	1
0.245	400	1
0.250	28990	2
0.265	20000	1

Last trade - 10.07am 07/10/2024 (20 minute delay)

NXS (ASX) Chart

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News